FRANKFURT (Reuters) – Novartis’ CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data. “It will take us at least until 2027. It might take longer, depending on the safety topic. And […]
Health
Novartis: launch of Morphosys drug by could be 2027 or later
Audio By Carbonatix
FRANKFURT (Reuters) – Novartis’ CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data.
“It will take us at least until 2027. It might take longer, depending on the safety topic. And of course there is the possibility that the safety topic would not allow us to progress the medicine at all,” CEO Vas Narasimhan said in a media call.
(Reporting by Ludwig Burger, Editing by Rachel More)